AlphAIAlphAI — Financial news for AI agents
stocktitan.netAUG 191 min read$PDSB

PDS Biotechnology (NASDAQ: PDSB) CEO takes interim finance role as CFO departs

PDS Biotechnology (PDSB) announced CFO Lars Boesgaard's resignation effective September 12, 2026. CEO Frank Bedu-Addo will serve as interim Principal Financial Officer, while Janetta Trochimiuk becomes interim Principal Accounting Officer with a $279,519.57 annual salary. Boesgaard's departure is not due to disagreements. Trochimiuk remains eligible for future equity awards.

Original reporting
stocktitan.net
Published Aug 19, 2026, 8:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 1:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$PDSB
Neutral
medium confidence
Mentioned
$PDSB
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$PDSBNeutralLow
01

Why it matters

The resignation is a material corporate event but does not include new financial data or strategic shifts.

02

Market read

Executive turnover may prompt short‑term trading interest but lacks immediate catalyst for large moves.

03

What to watch

No immediate financial impact disclosed; equity awards remain unchanged.

Relevance 7/10Novelty 7/10Timing: effective September 12, 2026

Background

The filing is an 8‑K disclosure of senior finance officer changes at PDS Biotechnology.

Company-level read

Ticker impact

$PDSBNeutralMedium confidence
Context

PDS Biotechnology announced CFO Lars Boesgaard resigned effective Sep 12, 2026 and appointed interim finance officers.

Expected impact

Potential modest downside pressure until new CFO is confirmed.

Evidence & confidence

CFO resignations are material but the interim appointments provide continuity; market reaction typically limited.

Market effects

Sector

May affect biotech sector sentiment as leadership stability is scrutinized.

Regional

Limited to US-listed biotech investors.

Global

Low global impact.

Counterpoint

What could challenge this read

The interim appointments could be seen as a positive sign of internal talent depth.

Key entities

  • person
    Lars Boesgaard

    Outgoing CFO, Principal Financial Officer and Principal Accounting Officer.

  • person
    Janetta Trochimiuk

    Current Controller appointed interim Principal Accounting Officer.

  • person
    Frank Bedu-Addo, Ph.D.

    CEO appointed interim Principal Financial Officer.

Read at source← All news

Related articles

SEP 22
$PDSBMedAI 8/10

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic…

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune

SEC EDGAR 8-K2 min
SEP 8
$BJDXMedAI 8/10

5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

rttnews.com3 min
SEP 8
$PDSBHighAI 8/10

80% survived at least two years in a 22-patient trial of PDS Biotech's cancer treatment

PDS Biotech (PDSB) secured a PIPE financing of up to $22.55M led by Nant Capital, with an initial closing of $11.55M expected by September 11, 2026. The funds will support late-stage development of PDS0301, following Phase 2 trial data showing 80% 24-month survival in 22 metastatic colorectal cancer patients. Nant Capital may designate two board members, including Dr. Patrick Soon-Shiong, while owning at least 15% of the common stock.

stocktitan.net2 min
AUG 13
$PDSBHighAI 8/10

PDS Biotechnology (PDSB) cuts R&D spend but warns on going concern, cash at $5.6M

PDS Biotechnology (PDSB) reported a $17.1M net loss for the six months ended June 30, 2026, with no product revenue. Operating expenses fell to $13.0M from $16.7M. Cash dropped to $5.6M from $26.7M at year-end 2025, and management said there is substantial doubt about its going concern. In June 2026, it redeemed $22.2M convertible debentures and issued a $6.0M 10% promissory note.

stocktitan.net6 min